Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
NCT06501326 on ClinicalTrials.gov · last registry update 2024-07-15
102 participants. Its estimated completion date, 31 October 2024, has passed with no update to the record. Primary outcome, as filed: Body weight. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Affiliated Hospital of Nantong University
- Sponsor type
- Other
- Enrollment
- 102
- Started
- 2023-11-01
- Primary completion
- 2024-10-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Body weight
Conditions studied
Non-alcoholic Fatty Liver Disease · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.